Mission: building a market-focused and technology-driven biopharmaceutical company with global manufacturing scale, delivering safe, effective, high-quality and affordable biologics to the patients around the world suffering from chronic endocrine and metabolic diseases

Market-driven and tech-enabled biologics R&D and resilient biomanufacturing capacity with later stage clinical trials of 2 protein therapeutics in EU

Global presence and experienced management team with leading industry experts from biopharma companies in China, US, Germany and Japan

World leading Epro genetic engineering platform technology meeting CMC requirements by EMA, FDA and NMPA

10+ biological products in pipeline addressing US$100 billion potential of the fast-growing market worldwide of endocrine and metabolic diseases such as diabetes

Commercial GMP commercial production lines in China and EU (CDMO) 

320-ton world-class fermentation capacity in Japan